These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Enhancement of the T cell response to a mycobacterial peptide by conjugation to synthetic branched polypeptide.
    Author: Wilkinson KA, Hudecz F, Vordermeier HM, Ivanyi J, Wilkinson RJ.
    Journal: Eur J Immunol; 1999 Sep; 29(9):2788-96. PubMed ID: 10508253.
    Abstract:
    A peptide-based approach towards improving the immunodiagnosis of, and vaccination against, tuberculosis faces the problems of MHC restriction of T cell recognition and the poor immunogenicity of peptides in the absence of adjuvant. We sought to compensate this by the use of synthetic branched polypeptides of the poly[Lys-(Xi-DL-Alam)] type, containing a glutamic acid residue (EAK), and further modified either by succinylation (SucEAK) or acetylation (AcEAK). These carriers were conjugated to two permissively recognized peptides of Mycobacterium tuberculosis. The 38p350 - 369-SucEAK conjugate enhanced IFN-gamma production more than 13-fold (from 22.6 to 294 pg / ml, p = 0.001) in peripheral blood mononuclear cells from healthy subjects, and 8.7-fold (p = 0. 012) in cells from tuberculosis patients. The effect was dependent on the carrier used and on covalent linkage of SucEAK to 38p350 - 369. An increased response occurred best in cells from subjects bearing at least one HLA-DR allele for which 38p350 - 369 had high binding affinity and required cellular processing of the conjugate as inhibitors (chloroquine and wortmannin) blocked the IFN-gamma response. SucEAK conjugation of peptide 16p91 - 110 did not significantly increase IFN-gamma production, indicating that the ability of conjugation to enhance the response was peptide structure dependent. These data indicate that the use of SucEAK polymer coupled with permissively recognized peptides could contribute to the development of an improved immunodiagnostic or vaccine reagent for tuberculosis.
    [Abstract] [Full Text] [Related] [New Search]